6 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Within triple-negative breast cancer, LAR is a research RNA profile with luminal and androgen-related expression. It is different from AR protein staining or apocrine histology, and a label alone does not establish benefit from an antiandrogen.
LAR is a research expression profile enriched for luminal and androgen-related programmes despite the receptor-defined TNBC context. It appears in the original six-group TNBCtype system and the four-profile TNBCtype-4 refinement. Different classifiers also use an LAR label; retain the actual method instead of assuming that shared names create identical groups.
The defining 2011 experiments found bicalutamide sensitivity in representative LAR cell lines. The 2016 retrospective pooled neoadjuvant analysis reported pathological complete response in 29 percent of LAR cases (95 percent confidence interval 17 to 41), versus 41 percent for BL1 (33 to 51) and 18 percent for BL2 (9 to 28). These are specified historical datasets and treatments, not universal response probabilities.
| Setting | Approach | Guideline |
|---|---|---|
| Stage II to III | As for triple-negative disease; the subtype's lower pathological complete response rate is a research observation. | not mapped |
| Metastatic, androgen receptor-positive (trials only) | Bicalutamide or enzalutamide showed clinical benefit in single-arm phase 2 trials: 19 percent at six months with bicalutamide, and at 16 weeks with enzalutamide 25 percent of all enrolled patients and 33 percent of the evaluable subgroup; not approved for breast cancer, so within a trial or after the approved options. | not mapped |